| Identification | Back Directory | [Name]
vasotocin, (beta-mercapto-beta,beta-cyclopentamethylenepropionic acid)-O-methyl-Tyr(2)-Thr(4)-Orn(8)-Tyr(9)-NH2 | [CAS]
114056-26-7 | [Synonyms]
OVTA
Ota-vasotocin
b-Mercapto-b,b-cyclopentaMethylene-propionyl-Tyr(Me)-Ile-Thr-Asn-Cys-Pro-Orn-Tyr-NH2
vasotocin, (beta-mercapto-beta,beta-cyclopentamethylenepropionic acid)-O-methyl-Tyr(2)-Thr(4)-Orn(8)-Tyr(9)-NH2
L-Tyrosinamide, N-[2-(1-mercaptocyclohexyl)acetyl]-O-methyl-L-tyrosyl-L-isoleucyl-L-threonyl-L-asparaginyl-L-cysteinyl-L-prolyl-L-ornithyl-, cyclic (1→5)-disulfide
(2S)-N-[(2R)-1-[(2S)-2-[[(2S)-5-amino-1-[[(2S)-1-amino-3-(4-methoxyphenyl)-1-oxopropan-2-yl]amino]-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-sulfanylidenepropan-2-yl]-2-[[(2S,3R)-3-hydroxy-2-[[(2S,3S)-2-[[(2S)-3-(4-hydroxyphenyl)-2-[[2-(1-sulfan
(2S)-N-[(2R)-1-[(2S)-2-[[(2S)-5-amino-1-[[(2S)-1-amino-3-(4-methoxyphenyl)-1-oxopropan-2-yl]amino]-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-sulfanylidenepropan-2-yl]-2-[[(2S,3R)-3-hydroxy-2-[[(2S,3S)-2-[[(2S)-3-(4-hydroxyphenyl)-2-[[2-(1-sulfanylcyclohexyl)acetyl]amino]propanoyl]amino]-3-methylpentanoyl]amino]butanoyl]amino]butanediamide | [Molecular Formula]
C54H79N11O13S2 | [MDL Number]
MFCD00076757 | [MOL File]
114056-26-7.mol | [Molecular Weight]
1154.4 |
| Hazard Information | Back Directory | [Description]
Ota-vasotocin is a ligand used in quantitative receptor autoradiography for oxytocin receptors. | [Uses]
(d(CH2)51,Tyr(Me)2,Thr4,Orn8,Tyr-NH29)-Vasotocin is an oxytocin antagonist and can be used for the research of sexual behavior[1]. | [in vivo]
(d(CH2)51,Tyr(Me)2,Thr4,Orn8,Tyr-NH29)-Vasotocin (50-1000 ng; Intra-MPOA; 1 μL) inhibits certain aspects of male sexual behavior in rats[1].
(d(CH2)51,Tyr(Me)2,Thr4,Orn8,Tyr-NH29)-Vasotocin (100 ng; i.c.v.; 1 μL) effectively suppresses hypoalgesia following copulatory behavior in male rats[2]. | Animal Model: | Adult Long–Evans/Blue-Spruce rats[1] | | Dosage: | 50 ng, 200 ng, and 1 μg | | Administration: | Intra-MPOA (medial preoptic area) injection, 1 μL | | Result: | Significantly increased intromission latency and anogenital investigation at 1 μg dose. Significantly decreased intromission ratio (2) at all doses. |
| Animal Model: | Adult male and female Long-Evans rats (8 weeks old, 220–260 g BW)[2] | | Dosage: | 100 ng | | Administration: | Intracerebroventricular injection, 1 μL | | Result: | Was effective in reducing pain threshold heightened by copulatory behavior. |
| [References]
[1] Gil M, et al. Oxytocin in the medial preoptic area facilitates male sexual behavior in the rat. Horm Behav. 2011 Apr;59(4):435-43. DOI:10.1016/j.yhbeh.2010.12.012
[2] Futagami H, et al. Oxytocin mediates copulation-induced hypoalgesia of male rats. Neurosci Lett. 2016 Apr 8;618:122-126. DOI:10.1016/j.neulet.2016.03.007 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|